Cardiome Pharma up 30% in pre-market on positive drug trial results
Cardiome Pharma Corp. (Nasdaq:CRME) shares are up more than 30% in pre-market trading today after the company’s early report of positive clinical results from its Phase 2b study of vernakalant, a drug used to treat atrial fibrillation. The Canada-based drug research and development company said oral vernakalant was well-tolerated in the population studied and that the 500mg dose decreased the rate of atrial fibrillation relapse. Atrial fibrillation is a cardiovascular disorder that can cause blood clots or strokes.
Ahead of today’s opening, shares of Cardiome Pharma are at $10.85, up $2.41 from Friday’s close. During the past year, the stock has ranged from $5.78 to $12.62.
For detailed price information and recent news stories about Cardiome Pharma Corp., click CRME.
